<DOC>
	<DOC>NCT01076088</DOC>
	<brief_summary>This study will assess the efficacy and safety of initial treatment with sitagliptin and metformin in patients with type 2 diabetes mellitus in China. The primary hypothesis is that after 24 weeks, initial co-administration treatment with sitagliptin and metformin provided greater reduction in hemoglobin A1C (A1C) compared to initial treatment with sitagliptin alone and with metformin alone.</brief_summary>
	<brief_title>Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>has type 2 diabetes mellitus is male, a female who cannot have children, or a female who agrees to use birth control during the study is not on an antihyperglycemic agent (AHA) (hemoglobin A1c [A1C] 7.511.0%) or on oral single AHA (A1C 7.010.5%) or lowdose AHA combination therapy (A1C 7.010.0%) Patient has type 1 diabetes mellitus or ketoacidosis Patient is taking a dipeptidyl peptidase4 (DPP4) inhibitor (such as sitagliptin) Patient is on a weight loss program not in the maintenance phase or on a weight loss medication Patient has a history of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer Patient is HIV positive Patient is pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>